Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Sanofi, GSK variant-specific COVID shot found effective against Omicron

Stock Markets Jun 24, 2022 09:56
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier

(Fixes typographical error in media identifier)

By Natalie Grover

PARIS/LONDON (Reuters) -Late-stage data on an experimental COVID-19 vaccine from Sanofi (EPA:SASY) and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

The so-called bivalent vaccine targets the Beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

When used in people who previously had COVID, the results were stronger. The vaccine generated an efficacy rate of 75.1% against symptomatic COVID and 93.2% in Omicron-confirmed symptomatic cases, the companies said.

"Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.

Sanofi's Paris-listed shares and GSK's London-listed shares were both up more than 1% in morning trading.

Earlier this month, the bivalent vaccine showed potential in two trials to protect against the virus' main variants of concern - the Omicron BA.1 and BA.2 strains - when used as a booster shot.

Sanofi and GSK, two of the world's biggest vaccine makers, are hoping to gain a foothold in the market for next-generation variant-focused COVID shots, after falling behind competitors including Moderna (NASDAQ:MRNA), AstraZeneca (NASDAQ:AZN) and Pfizer-BioNTech, in the original race to contain the pandemic.

The new data supporting the bivalent vaccine will be submitted to regulatory authorities with the hope of making the shot available later this year, the companies said on Friday.

Sanofi and GSK's original COVID vaccine is already under review by the European Medicines Agency.

The companies have bet that this bivalent vaccine moulded on the now-supplanted Beta variant will confer broad protection against future viral strains on the basis that Beta expresses similar mutations across multiple variants of concern, including Omicron.

Sanofi, GSK variant-specific COVID shot found effective against Omicron
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email